UNSPSC 51432308: Remikiren

This classification denotes a protease inhibitor and antihypertensive agent with the molecular formula C33H50N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LC7FBL96A4, chemically known as 1h-imidazole-4-propanamide, n-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1s-(1r*(r*(r*)),2s*,3r*))- but generally known as remikiren, which bears US NIH Compound Identifier 5462340.

UNSPSC 51432308 Remikiren, a Commodity code, spans pharmaceutical procurement by state and local health agencies, with recent activity centered on emergency medications, pharmacy benefit program modernization, and generic multi-source pharmaceutical supply agreements. State and local governments buy specific branded or generic pharmaceuticals—in this case, emergency life support medications—through sealed competitive bids, requests for information, and cooperative purchasing vehicle agreements that typically require compliance with FDA manufacturing standards, expiration-date minimums, chain-of-custody protocols, and Safety Data Sheet documentation. Issuing bodies include municipal fire-rescue departments, state health agencies, and multi-state cooperative purchasing alliances; the City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Department of Administration (administering MMCAP, a multi-state cooperative) appear as recent buyers. The procurement mix spans immediate inventory needs for emergency responders, exploratory market research for pharmacy benefit program redesign, and standing supply agreements serving multiple state and local participating members.

Recent opportunities show geographic spread across Florida, Texas, and Minnesota with national scope through cooperative vehicles. The City of Tampa issued IFB 26-P-00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials—with a $40,000 estimated contract value and a 5 percent Small Local Business Enterprise bid discount capped at $10,000. The Texas HHS Commission posted RFI HHS0017013 (closed April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, requiring NDC-specific pricing, cGMP and DSCSA compliance certification, and coverage through participating state and local facilities in Minnesota and Oregon.